Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors

Cytochrome P450 17A1 (CYP17A1) is an important target in the treatment of prostate cancer because it produces androgens required for tumour growth. The FDA has approved only one CYP17A1 inhibitor, abiraterone, which contains a steroidal scaffold similar to the endogenous CYP17A1 substrates. Abirater...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonomo, Silvia, Hansen, Cecilie H., Petrunak, Elyse M., Scott, Emily E., Styrishave, Bjarne, Jørgensen, Flemming Steen, Olsen, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942611/
https://www.ncbi.nlm.nih.gov/pubmed/27406023
http://dx.doi.org/10.1038/srep29468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942611/
https://www.ncbi.nlm.nih.gov/pubmed/27406023
http://dx.doi.org/10.1038/srep29468

Ejemplares similares